Pfizer, Endo Unit Duck MDL Claims Over Testosterone Drugs
Law360, New York (November 12, 2015, 11:54 PM EST) -- An Illinois federal judge overseeing multidistrict litigation over heart health risks and injuries allegedly caused by testosterone drugs made by Pfizer and an Endo unit has ruled the claims against them are preempted because the companies did not have the power to unilaterally strengthen their warnings.
U.S. District Judge Matthew Kennelly on Nov. 9 granted a motion to dismiss that was filed by Pfizer Inc., its unit Pharmacia & Upjohn, and Endo Pharmaceuticals Inc. unit Auxilium Pharmaceuticals Inc. against claims by consumers that they marketed their drugs Depo-Testosterone and Testopel, respectively, without sufficiently warning about their alleged cardiovascular risks.
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!